Shares of Athersys, Inc. (NASDAQ: ATHX) surged to end the first quarter on Thursday, closing ahead by 12 percent at $1.68 as volume swelled to 3.7 million on the last day of March. No announcements were made by the company. What appears to be happening is a growing awareness of Athersys as it maneuvers through
If the $21 billion global life sciences market is like a freight train, then microarrays can be thought of as the tracks. Microarrays are collections of microscopic DNA and protein spots attached to a solid surface that are used to simultaneously measure the expression levels of a large number of genes and proteins or to
Cardium Therapeutics (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on unlocking the value in innovative medical assets, acquired To Go Brands® in October 2012. Since then, the company has expanded the product portfolio to include over 25 nutraceutical powder mixes, supplements and chews to support a healthy lifestyle in today’s
Cancer, cardiovascular diseases and autoimmune diseases are among the most exciting fields in the pharmaceutical industry. While large and small molecule drugs have addressed targeted needs, the market is fragmented and lacks a unified platform
Vycor Medical Inc. (OTCQB: VYCO), a medical device company with a suite of FDA approved products, recently announced that Ohio State University has commenced an animal study which the Company hopes will support its ViewSite™
RXi Pharmaceuticals Corporation (OTC Markets: RXII), a biotechnology company focused on innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently announced that CEO Dr. Geert Cauwenbergh would discuss the development of RXI-109 at
Arrayit Corp. (OTC Markets: ARYC) reported revenues that jumped 66% to $942,916 during the first quarter, with net income that swung from a loss of $1,344,651 to a profit of $235,478 year over year. With
The pharmaceutical industry is largely centered on blockbuster drugs, with the top 20 drugs in the U.S. accounting for nearly $320 billion in sales in 2011. With five of those 20 drugs losing patent protection
RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, reported significant progress during the first quarter as it nears the
AtheroNova Inc. (OTCQB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, has spent the last few months building up
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major medical needs using RNA-targeted technologies, has been building awareness in both the scientific and investment communities at
Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on unlocking the value in medical assets, has pioneered a new gene therapy targeting heart disease that takes a different approach than
Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on unlocking the value in innovative medical assets, continues to expand awareness of the clinical benefits of its Excellagen® product
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announces that they will be presenting an overview of
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announces that it will be holding its first Investor and
© 2012 Emerging Growth Corp. All rights reserved.